case 8 - prostate cancer Flashcards

1
Q

what is the function and features of the prostate gland

A

walnut sized gland located behind the base of the penis, infront of the rectum and below the bladder
Surrounds the urethra
Primary function; produce seminal fluid, the liquid in semen that protects, supports and helps transport sperm

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the risk factors for prostate cancer

A

age
Race
Family history
Nationality
Genetics - BRACA1 and 2
Diet, exercise, obesity

1 in 8 men in the UK are diagnosed with prostate cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are the lower urinary tract symptoms for prostate cancer

A

Obstructive - feel like they can’t empty the bladder etc
Irritative - frequency, discomfort or blood in urine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are the other symptoms of prostate cancer

A

metastatic
Pain etc
systemic
Fatigue, weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

how is prostate cancer diagnosed

A

history
DRE
PSA - first three are done in primary care
Multi parametric MRI
Biopsy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

when does PSA increase

A

benign prostatic hypertrophy
Age
Prostatitis
Ejaculation
DRE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

when does PSA decrease

A

drugs - finasteride, dutasteride
Obesity
Herbal preparations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what can screening lead to

A

Overdiagnosis
Over treatment
consider targeted PSA screening in high risk populations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the MRI techniques used

A

T1 & T2 images
Functional imaging
Dynamic contract enhanced DCE
Diffuse weighted imaging DWI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are the prostate biopsies used

A

transrectal ultrasound guided TRUS biopsy
Biopsy taken through the rectal wall under ultrasound guidance
About 12 samples taken
template biopsy
Transperineal
Multiple samples taken

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the score system used for prostate cancer and what does this tell us

A

Gleason score - used for prostate cancer
Grading system used to define aggressiveness
Score of 3-5 are considered cancerous
Addition of 2 most common scores = Gleason score
Lowest is 6 and highest Is 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is stage 1

A

cancer confined to prostate T1a-2a
PSA <10
Grade group 1 = 3+3=6

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is stage 2

A

*Stage IIA
–T1a-2a
–PSA 10-20
–Grade group 2

*Stage IIB
–T1-2
–PSA <20
–Grade group 2

*Stage IIC
–T1-2
–PSA <20
–Grade group 3-4

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what is stage 3

A

*Stage IIIA
–T1-2
–PSA >20
–Grade group 1-4

*Stage IIIB
–T3-4
–Grade group 1-4

*Stage IIIC
–Grade group 5 = 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what is stage 4

A

Stage IV prostate cancer - means cancers that have metastasised
- most common place for prostate cancer spread is lymph nodes and bones

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what is low risk for prostate cancer

A

*Low Risk:
–T1-T2a and Gleason score 6 and PSA < 10 ng/ml

17
Q

what is high risk for prostate cancer

A

*High Risk:
–T3a or Gleason score 8-10 or PSA > 20

18
Q

*Gonadotrophin releasing hormone agonists (GnRHa) / Luteinising hormone releasing hormone agonists (LHRHa)
–Stimulate pituitary to produce LH
–LH stimulates testicles to produce testosterone
–Chronic exposure to LHRH leads to desensitisation + ↓LH and subsequent ↓testosterone
–May cause testosterone flare so need to give with androgen blocker
what is intermediate risk for prostate cancer

A

–T2b-T2c or Gleason score 7 or PSA 10-20

19
Q

what is the treatment for low/intermediate risk disease

A

radical prostatectomy
External beam radiotherapy
Brachytherapy
Active surveillance

20
Q

what is active surveillance of

A

regular monitoring
PSA
DRE
mpMRI
Biopsy
Constantly monitored and if progresses then active treatment is used

21
Q

what is brachytherapy

A

*Low dose rate
–Implanting radioactive source into the prostate
Most of their activity is gone in a few weeks
Have to have a general anaesthetic

*High dose rate (intermediate/high risk disease)
–Used as monotherapy
–Or in combination with EBRT

22
Q

what is external beam radiotherapy

A

OP treatment
5-37 fractions (treatments)
No anaesthetic
No catheter
Often in combination with ADT

23
Q

what is the surgery done

A

Robotic Assisted Laparoscopic Prostatectomy (RALP)
Surgeon operates from a console with a 3-D screen.
Grasp controls to manipulate surgical tools within the patient.
Robotic arms translate finger, hand, and wrist movements.
Very High-Precision
Less blood loss and less stay in hospital

24
Q

what is done if intermediate/high risk disease

A

localised disease with higher risk of disease progression
Important to adequately stage disease
Radiotherapy + ADT
RALP with lymph node dissection

25
Q

what is androgen depravation therapy

A

*>95% newly diagnosed prostate cancer will respond to treatment with androgen depravation therapy (ADT).
*2 mechanisms for preventing androgens:
–Reduce the level of androgens
–Block the androgens from binding
Most prostate cancers when they first present are hormone sensitive cancers

26
Q

what reduces the levels of testosterone and what is the process

A

*Gonadotrophin releasing hormone agonists (GnRHa) / Luteinising hormone releasing hormone agonists (LHRHa)
–Stimulate pituitary to produce LH
–LH stimulates testicles to produce testosterone
–Chronic exposure to LHRH leads to desensitisation + ↓LH and subsequent ↓testosterone
–May cause testosterone flare so need to give with androgen blocker

27
Q

what are the LHRH agonists

A

zoladex
Prostap - 4/52 or 12/52 (every four weeks etc)
Decapeptyl - 4/52, 12/52, 6/12

28
Q

what are the treatments that reduce the level of testosterone

A

*GnRH/LHRH antagonists
–Prevent LHRH binding to pituitary gland
–↓LH
–↓Testosterone
–No Testosterone flare

*Degarelix
–240mg initial dose (2x120mg SC)
–80mg 4/52
Is very expensive and has to be given every four weeks

29
Q

what are the androgen blockers

A

*Bicalutamide 50mg or 150mg OD
*Cyproterone Acetate 100mg TDS
*Used to reduce testosterone flare
*Directly block androgen receptor on cell surface
*3-4/52 prior to and after LHRHagonist

30
Q

what are ADT side effects

A

*Sexual
–Decreased libido
–Erectile dysfunction

*Psychological
–Lack of initiative
–Emotional lability
–Decreased memory and cognitive function

*Metabolic
–Lipid changes
–Diabetes mellitus

Physical
–Hot flushes
–Fatigue
–Weight gain
–Hair changes
–Breast pain
–Decreased muscle mass
–Decreased bone mineral density
–Decreased penile size

31
Q

what is metastatic prostate cancer and what are the features

A

*Disease has spread outside the prostate
*Not curable
*Aim of treatment: Disease control
*Median Survival ~ 5years
*Hormone Sensitive
*Castrate Resistant - this is when cancer progresses
*ADT is backbone of treatment

32
Q

what is given for hormone sensitive metastatic prostate cancers

A

*ADT
*Chemotherapy – Docetaxel
*Novel Hormones – Abiraterone, Apalutamide, Darolutamide, Enzalutamide
Radiotherapy to the prostate only

STAMPEDE trial - multi-arm, multi-stage stage 3 trial.

33
Q

what is given for castrate resistant metastatic prostate cancer

A

*ADT - still carry this on
*Supportive Care – analgesia, antiemetics etc
*Chemotherapy – Docetaxel, Cabazitaxel
*Novel Hormones – Abiraterone, Apalutamide, Darolutamide, Enzalutamide
*Radioisotopes – Radium 223 - preferentially taken into bone and emit alpha particles which act on DNAalpha (best treatment), Lu-PSMA
*Radiotherapy – to painful bone metastases

34
Q

what is castrate resistant metastatic prostate cancer

A

*12-18 months post ADT initiation is when cancer becomes resistant to the ADT - this is why its called castrate resistant MPC
*Rising PSA despite castrate levels of testosterone (<0.5nmol/L)
*Androgen receptor amplification
*Androgen receptor mutations
*Intratumoral androgen production
*Other growth signals take over
*Median Survival 3 years